Riley Hill, MD
Internal Medicine · Broken Arrow, OKNPI 1508865361
Payments from drug & device makers
Across 707 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- Lilly USA, LLC$1K
- Pfizer$1K
- Boehringer Ingelheim$856
- Johnson & Johnson$649
- plus $7K from 52 others
What the payments were for
- Food & beverage$13,45399%
- Education$1681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$597
- JARDIANCE$227
- DEXCOM G6 TRANSMITTER$148
- CHARTIS CATHETER$131
- PULMONX CHARTIS TABLET CONSOLE$131
- ZEPHYR ENDOBRONCHIAL VALVE$131
- ZEPHYR DELIVERY CATHETER$131
- XARELTO$125
- NURTEC ODT$125
- VYEPTI$124
- QULIPTA$114
- UBRELVY$114
How this compares
$13,621 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 165 | $199,821 |
| EliquisApixaban | 190 | $193,429 |
| XareltoRivaroxaban | 127 | $142,591 |
| OzempicSemaglutide | 108 | $112,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $90,808 |
| MounjaroTirzepatide | 66 | $85,283 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 85 | $79,443 |
| JanuviaSitagliptin Phosphate | 73 | $78,009 |
| FarxigaDapagliflozin Propanediol | 61 | $62,311 |
| TrulicityDulaglutide | 44 | $53,191 |
| CreonLipase/Protease/Amylase | 26 | $43,364 |
| EntrestoSacubitril/Valsartan | 28 | $38,531 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $28,799 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $27,339 |
| KerendiaFinerenone | 25 | $27,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat | $856 | $236,501196 claims |
| PfizerEliquis, Premarin | $1,024 | $208,935230 claims |
| Johnson & JohnsonXarelto | $649 | $142,591127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,276 | $138,474110 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $235 | $118,036107 claims |
| Novo NordiskOzempic | $363 | $112,785108 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,760 | $82,07591 claims |
| AbbVieCreon, Linzess, Synthroid | $1,526 | $80,729182 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $267 | $79,44385 claims |
| MerckJanuvia | $401 | $78,00973 claims |
| NovartisEntresto | $414 | $38,53128 claims |
| BayerKerendia | $263 | $27,15725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Broken Arrow
- Ranilo VasquezBroken Arrow$15K
- Rim TabbaaBroken Arrow$12K
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.